missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18518655

CD133 Antibody (217106) [DyLight 350], Novus Biologicals™

Rat Monoclonal Antibody

Brand:  Novus Biologicals FAB11332D

Product Code. 18518655

  • € 663.00 / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

CD133 Monoclonal antibody specifically detects CD133 in Mouse samples. It is validated for Flow Cytometry, Immunohistochemistry, CyTOF
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CD133
Monoclonal
DyLight 350
50mM Sodium Borate
Rat
Protein A or G purified from hybridoma culture supernatant
RUO
Primary
Mouse
Purified
Flow Cytometry, Immunohistochemistry, CyTOF
217106
Flow Cytometry, Immunohistochemistry, CyTOF-ready
AC133 Stargardt disease 4 (autosomal dominant), CD133, CD133 retinal 2, prominin (mouse)-like 1, prominin 1
Chinese hamster ovary cell line CHO-derived recombinant mouse CD133, Accession # O54990
0.1 mL
Autophagy, Cancer, Cardiovascular Biology, Cellular Markers, Cellular Signaling, Core ESC Like Genes, Cytokine Research, Hematopoietic Stem Cell Markers, Immunology, Innate Immunity, Lysosome Markers, Neuronal Cell Markers, Neuroscience, Stem Cell Markers
8842
Store at 4°C in the dark.
IgG2b
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.